Lancet Oncol: The efficacy of carfilzomib, darelimumab and dexamethasone in the treatment of relapsed or refractory multiple myeloma

Although the treatment options for multiple myeloma have made some progress in recent years, the demand for the treatment of patients with relapsed or refractory multiple myeloma has not been met, especially those who have been exposed to lenalidomide or are refractory to treatment.

The CANDOR study is a randomized, multi-center, open-label Phase 3 clinical trial that aims to compare carfilzomib, darelimumab, and dexamethasone (KdD) with carfilzomib and dexamethasone (Kd) Efficacy and safety in the treatment of patients with relapsed or refractory multiple myeloma

Patients with relapsed or refractory multiple myeloma who were over 18 years old were randomly (2:1) divided into two groups and received KdD or Kd treatment

Progression-free survival of the two treatment groups

From June 13, 2017 to June 25, 2018, a total of 466 patients were recruited, of which 312 received KdD treatment and 154 received Kd treatment

Treatment-related adverse events

There were 268 (87%) and 116 (76%) patients in the KdD group and Kd group, respectively, who had ≥3 grades requiring emergency treatment-related adverse events; the most common was thrombocytopenia (76[25%] vs 25[ 16%]), hypertension (65[21%] vs 23[15%]), pneumonia (54[18%] vs 14[9%]) and anemia (53[17%] vs 23[15%])

Compared with the Kd regimen, the KdD regimen has a clear and continuous progression-free survival benefit in patients with relapsed or refractory multiple myeloma; the KdD regimen may become the emerging standard treatment for patients with relapsed or refractory multiple myeloma

Saad Z Usmani, et al.